Merrimack Pharmaceuticals, a pioneering biopharmaceutical company based in Cambridge, Massachusetts, has successfully raised $93.5 million in funding to advance its mission of revolutionizing cancer care. By leveraging its expertise in cancer pathways and biological markers, Merrimack is dedicated to developing targeted treatments that not only combat cancer effectively but also enhance the quality of life for patients and their families. This substantial funding will enable the company to propel its strategic initiatives further, focusing on understanding the intricate biological challenges posed by cancer, designing tailored therapeutic solutions, and advancing these solutions towards biomarker-selected patient populations. Currently, Merrimack鈥檚 robust pipeline includes four ongoing clinical studies across distinct cancer indications and six candidates in preclinical development, each aligned with the company鈥檚 commitment to delivering optimal outcomes. This investment underscores the industry鈥檚 confidence in Merrimack鈥檚 innovative approach and underscores the urgent need for effective, personalized cancer therapies. The funds will be allocated toward accelerating development timelines, expanding clinical trials, and enhancing research capabilities, positioning Merrimack at the forefront of biopharmaceutical innovation. With this latest funding achievement, Merrimack reaffirms its dedication to outthinking cancer, ensuring that patients receive not just treatment, but a pathway to a fulfilling life beyond their diagnosis. For more information, visit Merrimack鈥檚 website at www.merrimack.com or follow them on Twitter at @MerrimackPharma.
Revolutionizing Cancer Care: Merrimack Raises $93.5 Million in Funding
Recently funded 路 $93.5MBiopharmaceutical
Get the full Merrimack company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
